Category Archives: "Disease Modifying Therapies"

Best Practices Guideline on the Use of Neurofilament
Consortium of Multiple Sclerosis Centers (CMSC) Best Practices Guideline on the Use of Neurofilament Biomarkers in MS Erratum: This [...]
CMSC Consensus Statement on Neurofilament Biomarkers in Multiple Sclerosis
This consensus document was developed by an international panel of experts on neurofilament biomarker research and clinical applications in [...]
Guidance for the Use of Disease Modifying Therapies During the COVID-19 pandemic
People with MS have asked for guidance on the use of Disease Modifying Therapies (DMTs) during the COVID-19 pandemic. There are numerous [...]
2019 CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis
This guideline was developed by a group of multiple sclerosis (MS) specialists, convened by the Consortium of Multiple Sclerosis Centers [...]
A Survey of Risk Tolerance to Multiple Sclerosis Therapies
NARCOMS, the CMSC Patient Registry, is led by a team of world-renowned MS clinicians and researchers.  Date from NARCOMS has provided the [...]
AAN Issues New Guideline on Complementary and Alternative Medicine in MS
According to a new AAN guideline, Complementary and Alternative Medicine in Multiple Sclerosis, there is little evidence for the [...]
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM